Tirzepatide Resources

    Everything you need to know about tirzepatide (Mounjaro, Zepbound) for weight loss. Evidence-based guides from medical experts.

    Cost

    Compounded Tirzepatide Cost 2026: $125/mo vs $1,060 Zepbound Cash

    Compounded tirzepatide cost May 2026: Trimi $125/mo annual ($1,500/yr) vs Zepbound ~$1,060/mo cash-pay. Same active ingredient (RxNorm 1928264), 503A community sterile compounding pharmacies (VialsRx, GreenwichRx).

    10 min
    GLP-1

    Buy Tirzepatide in Texas

    Buy compounded semaglutide online in Texas for $99/month. Learn about Texas telehealth laws, compounding pharmacy access, and how to start affordable GLP-1 weight loss treatment.

    10 min
    Comparisons

    Ro Tirzepatide Cost Without Insurance

    10 min
    Results & Timeline

    When Does Tirzepatide Appetite Suppression Start?: What to Expect Before You Judge Progress

    10 min
    Comparisons

    Real-World Results: Tirzepatide vs Semaglutide from Recent 2025 Studies

    Compare real-world outcomes of tirzepatide and semaglutide from 2025 observational studies.

    16 min
    GLP-1

    Buy Tirzepatide in Florida

    Buy compounded semaglutide online in Florida for $99/month. Florida telehealth access, compounding pharmacy regulations, and affordable GLP-1 weight loss treatment.

    10 min
    GLP-1

    Buy Tirzepatide in Illinois

    Buy compounded semaglutide online in Illinois for $99/month. Chicago and statewide telehealth access to affordable GLP-1 weight loss treatment.

    10 min
    Comparisons

    Does Hims Accept Insurance for Tirzepatide?

    10 min
    Comparisons

    Ro Tirzepatide Insurance Denials: What Readers Should Check

    10 min
    Cost & Insurance

    Tirzepatide Cost in Columbus, Ohio: What to Expect in 2026

    10 min
    Cost & Insurance

    Tirzepatide Cost in Denver, Colorado: What to Expect in 2026

    10 min
    Cost & Insurance

    Tirzepatide Cost in Indianapolis, Indiana: What to Expect in 2026

    10 min

    Ready to Start Your Journey?

    Get personalized tirzepatide treatment from licensed medical providers

    Get Started Today

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.

    What does the published clinical evidence show for compounded tirzepatide?

    Peer-reviewed evidence: Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022). Trimi offers compounded tirzepatide starting at $125/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. — SURMOUNT-1, NEJM 2022
    In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. — SURPASS-2, NEJM 2021
    Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. — SURMOUNT-OSA, NEJM 2024

    Key Takeaways

    • Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022)
    • In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. (Source: SURPASS-2, NEJM 2021)
    • Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. (Source: SURMOUNT-OSA, NEJM 2024)
    • Tirzepatide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Zepbound and Mounjaro). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 18, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    — Robyn Lynn CurtisFacebook
    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    — Sarah MillerFacebook
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2107519
    3. Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-023-02597-w
    4. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2023.24945
    5. Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2404881
    6. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) Prescribing Information. FDA.Read Study

    Was this article helpful?

    Keep Reading

    Retatrutide

    Retatrutide: Complete Guide

    Detailed comparison of retatrutide vs tirzepatide: 24.2% vs 22.5% weight loss, mechanism differences, side effects, cost projections, and whether to wait or start now.

    10 minRead More
    Cost & Insurance

    LillyDirect Zepbound 2026: $349-$549/mo Vials, Eligibility & Catch

    LillyDirect Zepbound vials cost $349-$549/mo self-pay in 2026 by dose. Eligibility rules, hidden caveats, and how compounded tirzepatide at $125/mo compares.

    10 minRead More
    GLP-1

    Buy Tirzepatide in Texas

    Buy compounded semaglutide online in Texas for $99/month. Learn about Texas telehealth laws, compounding pharmacy access, and how to start affordable GLP-1 weight loss treatment.

    10 minRead More
    Retatrutide

    Retatrutide: Complete Guide

    Side-by-side comparison of retatrutide, tirzepatide, and semaglutide: mechanisms, weight loss data, side effects, dosing, cost, and availability in 2026.

    10 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started